Overview

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Status:
Recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory follicular lymphoma (FL)

Phase:

Phase 2

Details

Lead Sponsor:

Xynomic Pharmaceuticals, Inc.

Treatments:

Abexinostat
Histone Deacetylase Inhibitors